ALVELTAMIG
UNII JS9TS9U9N4
Substance Identification & Data
This profile provides standardized clinical and technical data for Alveltamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) JS9TS9U9N4.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3062244-97-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
JS9TS9U9N4
3062244-97-4
N/A
Detailed Substance Profile
Preferred Name
ALVELTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
13944
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Alveltamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Alveltamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Alveltamig
Common Names & Synonyms
H-gamma1 heavy chain anti-DLL3 (H) (1-448) [VH (Homo sapiens IGHV3-30*03 (92.9%) -(IGHD)-IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01v, G1m17,1>G1m3,1 CH1 R120, CH3 D12, L14, 6-G1v39 CH2 F1.3, E1.2, S116, 14-G1v75 CH3 C5, 14-G1v72-5 E26, D88, E119 (CH1 R120 (215) (119-216), hinge 1-15 (217-231), CH2 L1.3>F (235), L1.2>E (236), P116>S (332) (232-341), CH3 Y5>C (350), D12 (357), L14 (359), K26>E (371), K88>D (410), K119>E (440) (342-446), CHS (447-448)) (119-448)], (221-219')-disulfide with L-kappa light chain anti-DLL3 (L') (1'-219') [V-KAPPA (Homo sapiens IGKV1-6*01 (78.8%) -IGKJ1*01 (91.7%), CDR-IMGT [11.3.9] (27'-37'.55'-57'.94'-102')) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'), V101 (196')) (113'-219')]; fused scFvhk-scFvhl-G1(h-CH2-CH3) heavy chain anti-DLL3 and anti-CD3E (H'') (1''-736'') [scFvhk anti-DLL3 (1''-244'') [VH anti-DLL3 (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.15] (26''-33''.51''-58''.97''-111'')) (1''-122'') -15-mer tris(tetraglycyl-seryl) linker (123''-137'') -V-KAPPA anti-DLL3 (Homo sapiens IGKV1-9*01 (85.3%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (164''-169''.187''-189''.226''-234'')) (138''-244'')] -6-mer (seryl-tetraglycyl-seryl) linker (245''-250'') -[scFvhl anti-CD3E (251''-504'') [VH anti-CD3E (Homo sapiens IGHV3-73*01 (87.0%) -IGHD -IGHJ4*01 (86.7%), CDR-IMGT [8.10.16] (276''-283''.301''-310''.349''-364'')) (251''-375'') -20-mer tetrakis(glycyl-lysyl-prolyl-glycyl-seryl) linker (376''-395'') -V-LAMBDA anti-CD3E Musmus/Homsap (Mus musculus IGLV1*01 (80.6%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (76.8%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (421''-429''.447''-449''.486''-494'')) (396''-504'')] -G1(h-CH2-CH3) (505''-736'') [Homo sapiens IGHG1*01v, G1m17,1>G1m3,1 CH3 L14, 15-G1v37 h S5, 14-G1v74 CH3 C10, 6-G1v39 CH2 F1.3, E1.2, S116, 14-G1v73-6 K12, K13, K84.2 (hinge 1-15 C5>S(509'') (505''-519''), CH2 L1.3>F (523''), L1.2>E (524''), P116>S (620'') (520''-629''), CH3 S10>C (643''), D12>K (645''), E13>K (646''), L14 (647''), D84.2>K (688'') (630''-734''), CHS (735''-736''))]];dimer (227-515'':230-518'':350-643'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
Immunoglobulin G1, trispecific, anti-(human Notch ligand DLL3) (human-mouse monoclonal anti-DLL3-(D139A) single-chain variable fragment VH-(GGGGS)3-VL) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen) (human-Mus musculus monoclonal anti-CD3-(SP34) single-chain variable fragment VH-(GKPGS)4-VL) fusion protein with immunoglobulin G1 [5-serine,19-phenylalanine,20-glutamic acid,116-serine,139-cysteine,141-lysine,142-lysine,184-lysine] (human γ1-chain C-region C-terminal fragment), (515→227′),(518→230′),(632→350′)-tris(disulfide) with immunoglobulin G1 [215-arginine,235-phenylalanine,236-glutamic acid,332-serine,350-cysteine,371-glutamic acid,410-apsartic acid,440-glutamic acid] anti-(human Notch ligand DLL3) (human-Mus musculus monoclonal anti-DLL3-(1D4) γ1-chain), (221′→219′′)-disulfide with human-Mus musculus monoclonal anti-DLL3-(1D4) κ-chain
alveltamig [INN]
immunoglobulin (H-gamma1_L-kappa)_(scFvhk-15mer-scFvhl-G1(h-CH2-CH3)), anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody, bispecific, trivalent
